| Outcome Measures: |
Primary: Net Clinical adverse event (NACE), Net Clinical adverse event (NACE) : all cause death, myocardial infarction, stent thrombosis, stroke, major bleeding (BARC 3,5), 1 year | Secondary: The rate of Each component of NACE, NACE : all cause or Cardiac death, myocardial infarction, stent thrombosis (definite, probable, possible), stroke (non-ischemic, ischemic), major bleeding (BARC 3,5), 1 year|The rate of key secondary efficacy endpoint : Major Efficacy end points, Cardiac death, myocardial infarction, stent thrombosis (definite or probable), stroke, 1 year|The rate of key secondary safety endpoint : Major safety end points, BARC bleeding (2,3,5), Fatal bleeding or intracranial hemorrhage, 1 year|The rate of Target lesion revascularization, 1 year|The rate of Target vessel revascularization, 1 year|The rate of Subgroup analysis of primary endpoint, key secondary efficacy, safety endpoint and, revascularization according to the CKD stage (lllb vs. iV or V), 1 year|The rate of Subgroup analysis of primary endpoint, key secondary efficacy, safety endpoint and, revascularization according to the clinical presentation (stable angina vs. acute coronary syndrome), 1 year|The rate of Subgroup analysis of primary endpoint, key secondary efficacy, safety endpoint and, revascularization according to the type of Stent (polymer free vs. durable polymer), 1 year
|
